Verified3

Stanford MEDICINE

Stanford Cancer Institute

Genitourinary

Version Date:
January 16, 2024

Prostate

Localized Treatment

Intact Prostate

PROS0107
Focal Laser Ablation of Prostate Cancer: EarlyFeasibility Study Using MRI/US ImageFusion for Guidance

PI:Sonn
Sponsor: Pending

NRGGU009
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk & Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

PI: Bagshaw
Sponsor: NRG

PROS0122
Open-Label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer

PI: Sonn
Sponsor: SpectraCure AB

PROS0124
Customized Ablation of the Prostate with the TULSA Procedure Against RadIcal Prostatectomy TreatmeNt: a Randomized Controlled Trial for Localized Prostate Cancer

PI: Sonn
Sponsor: Profound Medical, Inc.

Metastatic Hormone Sensitive

PROS0113
Phase III 177Lu-PSMA-617 +/- Standard of Care in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

PI: Iagaru
Sponsor: Novartis Pharmaceuticals, Corporation

PROS0108
Prostatic Artery Embolization in Treatment of LUTS in Prostate Cancer Undergoing Radiation Therapy

PI:Picel
Sponsor: Stanford University

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu